News & Events:ABBV

Teva, Allergan Settle Opioid Lawsuit With West Virginia

Teva Pharmaceutical Industries and AbbVie's Allergan unit reached a settlement worth $161.5 million to resolve claims the companies fueled an opioid epidemic in West Virginia, state attorney general Patrick Morrisey said on Wednesday.

Teva Pharmaceutical Industries and AbbVie's Allergan unit reached a settlement worth $161.5 million to resolve claims the companies fueled an opioid epidemic in West Virginia, state attorney general Patrick Morrisey said Wednesday.

NORTH CHICAGO, Ill. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVieAbbVie's (ABBV) mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow.

The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities class action lawsuit against AbbVie, Inc. (ABBV) on behalf of all persons and entities who purchased or otherwise acquired AbbVie (ABBV) securities between April 30, 2021, and August 31, 2021, inclusive. CLICK HERE TO SUBMIT YOUR ABBVIE LOSSES.

Why SpringWorks Shares Are Soaring Today Premarket

Here's a roundup of top developments in the biotech space over the last 24 hours: The FDA has requested additional information on the Chemistry Manufacturing and Controls of the newly manufactured INmune Bio Inc's  XPro1595. As part of the communication, the FDA placed the company's Investigational New Drug application for the Phase 2 trial of XPro in Alzheimer's Disease on clinical hold.

- SELECT-AXIS 2 highlights the efficacy and safety data of upadacitinib in patients with non-radiographic axial spondyloarthritis, and in patients with radiographic axial spondyloarthritis with an inadequate response to biologic disease-modifying antirheumatic drugs- SELECT-PsA 1 & 2 highlight the efficacy and safety data of RINVOQ at two years in psoriatic arthritis patients with an inadequate...

AbbVie has outperformed the market over the past 5 years by 7.1% on an annualized basis producing an average annual return of 17.45%. Currently, AbbVie has a market capitalization of $260.97 billion. Buying $1000 In ABBV: If an investor had bought $1000 of ABBV stock 5 years ago, it would be worth $2,226.33 today based on a price of $147.68 for ABBV at the time of writing.

  See all analyst ratings upgrades.   See all analyst ratings downgrades.   See all analyst ratings initiations.

Within the last quarter, AbbVie has observed the following analyst ratings: According to 8 analyst offering 12-month price targets in the last 3 months, AbbVie has an average price target of $169.38 with a high of $200.00 and a low of $140.00. Below is a summary of how these 8 analysts rated AbbVie over the past 3 months. This average price target has increased by 11.75% over the past month.

Abbvie Inc (ABBV): * ABBVIE PRESENTS POSITIVE DATA FROM PHASE 3 STUDY OF CARIPRAZINE FOR THE ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER AT 2022 APA ANNUAL MEETING Source text for Eikon: Further company coverage:

NORTH CHICAGO, Ill. AbbVie's (ABBV) supplemental New Drug Application for cariprazine was supported by two positive registration-enabling studies, of which one was Study 3111-301-001.

EMA's CHMP Recommends AbbVie's Upadacitinib For Ulcerative Colitis

Abbvie Inc (ABBV): * CHMP RECOMMENDS EUROPEAN COMMISSION APPROVAL OF UPADACITINIB FOR THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS. * CHMP POSITIVE OPINION IS BASED ON RESULTS FROM THREE PHASE 3 STUDIES: TWO FOR INDUCTION AND ONE FOR MAINTENANCE. * IF APPROVED BY EUROPEAN COMMISSION, THIS WOULD BE UPADACITINIB'S FIFTH THERAPEUTIC INDICATION IN EU.

NORTH CHICAGO, Ill.

On CNBC's "Halftime Report Final Trades," Kevin O'Leary, known as "Mr. Wonderful," said that consumer goods, especially baby powder and baby formula, have been "in the news lately." O'Leary added, "Nestle is a great trade name" and a global behemoth, with 50% of its sales in the US.

Biotech stocks advanced in the week ending May 22, defying the broader market retreat. The spread of the monkey pox virus in the U.S. and Europe sparked a rally in companies working on vaccine candidates against viruses. NanoViricides, Inc. also advanced strongly following positive clinical updates provided by the company.

The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities class action lawsuit in the United States District Court for the Northern District of Illinois against AbbVie, Inc. (ABBV) on behalf of all persons and entities who purchased or otherwise acquired AbbVie (ABBV) securities between April 30, 2021, and August 31, 2021, inclusive.

AbbVie Submits FDA Application For Continuous, 24-Hour Infusion Therapy For Parkinson's